Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Patricio F Reyes

Patricio F Reyes

Director
Alzheimer’s and Cognitive Disorders Program Karsten Solheim Dementia Research Chair
USA

Biography

Patricio F. Reyes, MD is a board certified Neurologist and Neuropathologist, and director Barrow Neurological Institute’s Alzheimer’s disease (AD) and Cognitive Disorders Program, and Neuropathology Research Laboratory. Before joining BNI he was professor of Neurology, Pathology and Psychiatry and director of Creighton University’s Center for Aging, Alzheimer’s disease and Neurodegenerative Disorders, and Brain Bank and held similar positions at Jefferson Medical College in Philadelphia. He is the American Academy of Neurology advocate for Minority Americans with AD and other dementias. His interests include characterizing the clinical manifestations of Alzheimer’s disease and other dementias, and investigating the structural, anatomical and neurochemical substrates of neurobehavioral symptoms. He is involved in clinical trials for AD and has established clinical programs for Hispanic patients and minority caregivers. These programs are important in identifying ethnic related risk factors for AD, understanding the vulnerability of brain regions affected in AD, and verifying the safety, tolerability and efficacy of pharmacologic agents in various races. In the laboratory, he is currently involved in verifying the histological, immunohistochemical, electronmicroscopy, and metabolic changes in the brain parenchyma of triple transgenic mouse model of Alzheimer’s disease and Acetylcholinesterase knockout mouse. We expect to determine early physiologic and ultrastructural alterations that lead to neuronal loss and formation of neuritic plaques, and neurofibrillary tangles, and hope that our data will be relevant to the development of more effective therapies in AD.

Research Interest

Neurology